Skip to main content
OpenTrials
Completed

NCT Number: NCT07225413

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

This study will evaluate whether 7 days of Rhodiola rosea (golden root) supplementation can improve resistance-exercise performance and cognitive function in resistance-trained men and women. Participants will complete four 7-day periods in a randomized, double-blind, crossover order: (1) no-capsule control, (2) placebo, (3) low-dose Rhodiola rosea, and (4) high-dose Rhodiola rosea. On day 7 of each period, they will report to the laboratory for performance testing that includes bench press and leg press 1-repetition maximum (1RM), a third set to failure at 60% 1RM, Tendo-derived mean and peak power, a 30-second Wingate test, and the paper-and-pencil Stroop Color-Word Test for executive function. Secondary outcomes include ratings of perceived exertion, readiness to perform (visual analog scale), and heart rate and blood pressure measured at rest and 1 minute after exercise. The central hypothesis is that short-term Rhodiola rosea, compared with control and placebo, will produce small but measurable improvements in strength, set-to-failure volume, and Stroop performance, with minimal changes in hemodynamics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 week–40 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Exercise Physiology and Nutrition Laboratory (EPNL) at Jacksonville State University

Jacksonville, Alabama, 36265, United States

About this study

Rationale: Rhodiola rosea is an adaptogenic plant extract that has shown modest, context-dependent effects on perception of effort, cognition, and exercise performance. Prior studies suggest that benefits may be more evident with acute or short-term administration; however, the results are heterogeneous. This study employs a within-subject approach in resistance-trained adults to minimize between-person variability and investigate potential dose-response effects over a short time frame.

Design overview: After screening and a familiarization visit, each participant completes four 7-day periods: (1) no-capsule control, (2) placebo, (3) low-dose RR, and (4) high-dose RR. Capsule periods are randomized and double-blind; the no-capsule control precedes capsule periods to avoid carryover of expectancy. Study staff, participants, and outcome assessors are blinded during capsule periods. On day 7 of each period, participants attend a single testing visit conducted under standardized conditions (time of day, pre-test instructions). Short-latency effects are targeted by scheduling capsule ingestion approximately 60 minutes before testing during capsule periods.

Intervention: Low- and high-dose RR are provided in identical-appearing capsules. Placebo capsules contain inert filler. Product identity, dose, and lot information are recorded in the Intervention section of the record. Capsule count and participant logs monitor adherence.

Standardization and compliance: Participants are asked to maintain their habitual training and diet and to refrain from using additional ergogenic aids for a period of 7 days. They record total energy and macronutrients for the three days before each testing day. Testing sessions follow a consistent order of tasks established during the familiarization phase. Resting vital signs are obtained after a seated rest; post-exercise measures are obtained 1 minute after completion of designated tasks.

Population: Resistance-trained adults (men and women) who meet eligibility criteria and provide informed consent. Additional eligibility details are specified in the Eligibility section of the record. The female hormonal status/menstrual phases are documented when available to aid in interpretation.

Data handling and analysis (overview): The primary analyses compare conditions within participants using linear mixed-effects models, with participant as a random effect and fixed terms for condition and period. Additional prespecified covariates (e.g., sex, pre-visit dietary intake) may also be included. Order and carryover are evaluated as appropriate. Missing data are handled using model-based methods consistent with the statistical plan.

Safety: Adverse events are monitored throughout each period, with procedures for reporting to the IRB per institutional policy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 18-40 years old
  • ≥2 years of consistent resistance training, including bench press and leg press/squat
  • Able to complete all four 7-day conditions and Day-7 testing in a crossover design
  • Willing to abstain from other performance supplements during the study
  • Provided written informed consent

Exclusion criteria

  • Diagnosed metabolic, cardiovascular, or thyroid disorders
  • Cardiac arrhythmias
  • Current prescription drugs with possible cardiovascular or neurocognitive effects
  • Smoking
  • Known or suspected sensitivity to Rhodiola rosea
  • Regular alcohol intake >12 drinks/week
  • Recent musculoskeletal injury that could limit resistance-exercise testing

Treatment and study plan

Rhodiola rosea (low dose)

Dietary Supplement

Participants will ingest a low-dose Rhodiola rosea extract (≈approximately 200 mg/day) once daily for 7 consecutive days. On day 7, ~60 minutes after the final dose, they will complete the exercise and cognitive testing battery (bench press, leg press, set to failure at 60% 1RM, Tendo power, 30-s Wingate, Stroop test, HR/BP, RPE). This intervention is used to determine whether short-term, lower-dose RR improves resistance performance and executive function compared with placebo and control.

Other names: Rhodiola rosea extract 200 mg

Rhodiola rosea (high dose)

Dietary Supplement

Participants will ingest a high-dose Rhodiola rosea extract (≈approximately 1,500 mg/day) once daily for 7 consecutive days. On day 7, ~60 minutes after the final dose, they will complete the same performance and cognitive testing battery. This arm allows dose-response comparison with the low-dose RR, placebo, and no-capsule control conditions.

Placebo capsules

Dietary Supplement

Participants will ingest matching placebo capsules once daily for 7 days. On day 7, ~60 minutes after capsule ingestion, they will complete the full testing battery. This intervention controls for expectancy, capsule handling, and timing.

Primary outcomes

  1. Load volume (kg) during 3rd set to failure at 60% 1RM

    Time frame: Day 7 of each 7-day period

    Participants performed bench presses and leg presses at 60% of their familiarization 1RM. On the 3rd set, they lifted to volitional failure; load volume was calculated as load (kg) × repetitions. Values after administration of low- and high-dose Rhodiola rosea were compared with those of the placebo and control groups.

  2. Wingate anaerobic test peak power

    Time frame: Day 7 of each 7-day period

    Participants completed a 30-s Wingate test on a cycle ergometer; peak power (W) was recorded. Values after low- and high-dose Rhodiola rosea were compared with those of the placebo and control to assess the effects on anaerobic performance.

  3. Executive function (Stroop Color-Word Test)

    Time frame: Day 7 of each 7-day period

    The paper-and-pencil Stroop Color-Word Test is administered (Word, Color, and Color-Word, 45 s each). The total number of correct responses across the three sections is recorded. Higher scores indicate better executive control.

Secondary outcomes

  1. Readiness to Perform (Visual Analog Scale, 0-100 mm)

    Time frame: Day 7 of each 7-day period

    Participants rated six items before testing on a 0-100 mm line anchored 0 = strongly disagree (worse) and 100 = strongly agree (better): (1) I slept well last night; (2) I am looking forward to today's workout; (3) I am optimistic about my future performance; (4) I feel vigorous and energetic; (5) My appetite is great; (6) I have little muscle soreness. Scores were recorded in millimeters; higher values indicate better readiness (greater agreement).

  2. Rating of Perceived Exertion (RPE) after resistance exercise

    Time frame: Day 7 of each 7-day period

    RPE is recorded 1 minute after the 3rd set of bench press and leg press using the Borg 6-20 scale. Higher values indicate greater perceived exertion.

  3. Resting Heart Rate

    Time frame: Day 7 of each 7-day period

    Seated/resting heart rate measured before testing. Unit: beats per minute (bpm). Higher values indicate higher HR.

  4. 1-Minute Post-Exercise Heart Rate

    Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).

    Heart rate was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: beats per minute (bpm). Higher values indicate higher HR.

  5. Resting Systolic Blood Pressure

    Time frame: Day 7 of each 7 days (pre-test).

    Seated/resting SBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher SBP.

  6. Resting Diastolic Blood Pressure

    Time frame: Day 7 of each 7 days (pre-test).

    Seated/resting DBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher DBP.

  7. 1-Minute Post-Exercise Systolic Blood Pressure

    Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).

    SBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher SBP.

  8. 1-Minute Post-Exercise Diastolic Blood Pressure

    Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).

    DBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher DBP.

  9. Adverse Events / Side-Effects-Frequency (0-5 Likert)

    Time frame: Day 7 of each 7 days (post-condition).

    Participants completed a side-effects questionnaire rating how often each symptom occurred using a 6-point scale (0 = none; 1 = minimal [1-2/week]; 2 = slight [3-4/week]; 3 = occasional [5-6/week]; 4 = frequent [7-8/week]; 5 = severe [≥9/week]). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more frequent). Each item was analyzed separately; an optional composite frequency score (item mean) was also recorded.

  10. Adverse Events / Side-Effects-Severity (0-5 Likert)

    Time frame: Day 7 of each 7 days (post-condition).

    Description: Using the same questionnaire, participants rated how severe each symptom was on a 6-point scale (0 = none; 1 = minimal; 2 = slight; 3 = moderate; 4 = severe; 5 = very severe). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more severe). Each item was analyzed separately; an optional composite severity score (item mean) was also recorded.

Sponsors and collaborators

Lead sponsor

Jacksonville State University

Other

Registry information

Official study title

Dose-Response Effects of Short-Term *Rhodiola Rosea* on Anaerobic Performance and Cognitive Function in Resistance-Trained Adults: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Nov 6, 2025
Registry last updated
Nov 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.